Skip to main content
Premium Trial:

Request an Annual Quote

Enigma Diagnostics Exclusively Licenses UK Defense Lab IP Supporting RT-PCR Systems

NEW YORK (GenomeWeb News) — Enigma Diagnostics yesterday said it has licensed a “broad range” of technologies from the UK’s Defense Science and Technology Laboratory that will give the company “much greater control” over IP “at the heart” of its real-time PCR systems.
 
The worldwide exclusive license covers 25 DSTL patents and patent applications. In particular, the license covers the Pyrostart, ResonSense, and Temperature Control, technologies, which Enigma called “important elements” of its RT-PCR systems.
 
These systems are being developed to rapidly detect and identify pathogens, including bacteria and viruses, in clinical, environmental, and biological samples, Enigma said.
 
The deal follows an initial license agreement that Enigma signed in 2004 with the group, which is a center of scientific excellence for the UK Ministry of Defense.
 
The new agreement, which will remain in place until 2026, enables Enigma to sub-license any of the technologies for PCR and non-PCR applications to potential partners and collaborators.
 
Enigma, which will obtain an undisclosed number of trademarks linked to the IP, will be able to patent improvements that it makes to any of the technologies.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.